Loading stock data…
GMED
$91.34+1.16 (+1.29%)
Market ClosedLast close May 1
Globus Medical, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Globus Medical, Inc. in the Healthcare sector is trading at $91.34. The stock is currently 10% below its 52-week high of $101.40, remaining 18.5% above its 200-day moving average. Technical signals show neutral RSI of 47 and bearish MACD signal, explaining why GMED maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 47) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$91.34
Potential Downside
19.3%
Whystock Fair Value$73.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$110.64+21.1%
Range$90.00 – $123.00
Fundamentals
Globus Medical, Inc. develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products comprising traditional fusion implants, such as pedicle scre...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.85B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
24.23
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
7.80%
Volume
Today's trading volume
906,981
Recent News
Stryker Q1 Earnings & Sales Miss Estimates on Cyber Disruption
SYK misses Q1 earnings and revenue estimates as a cyber incident disrupts production, dents margins, and slows growth despite gains across key segments.
Merit Medical Q1 Earnings & Revenues Beat Estimates, Sales View Up
MMSI tops Q1 estimates with 9% EPS growth and 7% revenue rise, while lifting its 2026 sales outlook amid steady segment and geographic gains.
ILMN Stock Up on Q1 Earnings & Revenue Beat, Margins Expand, '26 View Up
Illumina stock jumps after Q1 earnings and revenue beat, with margin expansion and raised 2026 outlook signaling continued growth momentum.
Omnicell Q1 Earnings & Revenues Top, Stock Up, Gross Margin Rises
OMCL posts Q1 earnings and revenue beat with surging margins and strong demand, sending shares sharply higher after results.
RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
Resmed beats Q3 earnings and revenue estimates with strong margin gains, yet shares slip post earnings despite growth across key segments.